Trial Profile
Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 03 Feb 2022 Results (n=75) assessing the relationship between mental status and feasibility of an intravitreal ranibizumab treat-and-extend regimen for nvAMD, published in the Advances in Therapy.
- 17 Aug 2019 Status changed from recruiting to completed.
- 19 Oct 2016 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.